Dr Lindsay Rosenwald | Lindsay Rosenwald Success & Achievements

Dr. Lindsay Rosenwald is one of The Most Prolific Leaders in the biotechnology field. With his humongous experience in starting up the companies and investing in small ventures, he has become the most influential leader in the Biotechnology market. He helped a lot of new companies by funding in the initial stages. He believes in funding new ventures and small companies as he feels that the small companies would change the status quo in the biotechnology market.

Dr. Lindsay also handles a wide range of financial portfolio. His portfolio includes venture capital, hedge fund and capital assets. This financial portfolio made him an influential person in the Wall Street, New York. Once he moved to Wall Street, New York, he started concentrating on the advanced research and development of biotechnology. His first venture  is one of the group companies that help in fund rising for the portfolio companies. With the company, Dr. Lindsay Rosenwald started numerous companies that are into advanced drug development and clinical research.

Dr. Lindsay is the founder of Rosenwald Foundation, which is a charitable foundation that helps most of the professionals who plan to excel in the biotechnology market. This is considered to be one of the most influential and helpful foundation in the biotechnology market. Apart from this, Lindsay has been serving as the director for several public and private limited companies. With the 20 years of experience, he helped a lot of MBAs, PhDs, to excel in the biotechnology field.

Dr. Rosenwald is the founder of a group of companies which are actively involved in the clinical research and drug development.  This is the reason why, Lindsay is considered to be the most successful and influential leader in the biotechnology and finance. His contributions to the biotechnology are incredible and humongous. Dr Lindsay is also known for getting the quick approvals form FDA to market the drugs.

Dr. Lindsay Rosenwald completed his Bachelor of Science and a Finance degree for Pennsylvania University in 1972 and later on, he moved to the Templeton School of Medicine to get his medical degree. With the finance and medical degree in hand, he started his own medical practice and ran it successfully for two years. This small medical practice is said to be the first entrepreneurial venture for Lindsay.

New York Times Article

This New York Times article goes over the appointment of Dr. Lindsay Rosenwald as the director of corporate finance at D. H. Blair & Company’s Wall Street firm at age 33.  It talks about his background and decision to become a biotech investor.

It discusses his Penn State background in finance but how he moved on with the thought of becoming a doctor.  Even while in school, however, Lindsay Rosenwald continued his work and interest in finance.  This was even commented on during his Abington Hospital internship.

It continued to mention how Dr. Lindsay Rosenwald established a private practice for two and a half years prior to coming to Wall Street as a securities analyst at Ladenburg & Thalmann prior to making the move to D. H. Blair & Company (a company specializing in venture capital and public offerings).

He made the shift because he wanted to be able to focus on investments in the health care industry.  Lindsay Rosenwald does admit, however, that he sometimes misses his patients, but specifies that the move to Wall Street was definitely what he wanted.

Various mentions are made in this article of Rosenwald’s background that prepared him so effectively for the Biotech industry, and goes into his early moves to and within Wall Street.

Reverse Merger Blog

This August, 2009 article from the reverse merger blog praises the massive reverse merger of Cougar Biotech.  The article specifies that the company was sold to Johnson and Johnson via reverse mortgage (using a Form 10 shell) for a total of $1 billion (US).

The article mentions the 2006 Form 10 shell reverse merger of Cougar as a further example of the use of this reverse merger construction.  It notes that the stock prices for Cougar have risen a full 145% since the merger was completed, and mentions some additional details of note in the merger.

It cites comments from Lindsay Rosenwald on the

In this report, Michael Brush, writer for MSN’s Money Central, talks about the benefits of examining industry insiders when making decisions for your stock portfolio.  He notes the records of major industry insiders in the past, with the notable “Insider Portfolio” beating the Dow Jones by over 900% over the 1986 to 2010 stretch.  The advice is relatively straightforward – buy what those in the know are buying, and sell what and when they’re selling.

Brush then continues to examine big hitters within the industry, mentioning Tom Ward of Chesapeake Energy and Lindsay Rosenwald..  He praises choices from both insiders, and mentions the Lindsay Rosenwald’s impressive record (with gains of 100% to 280% over a si month period, and short trades in two stocks hitting over a 60% gain).

Brush specifies specific stocks that Rosenwald, Ward, and other insiders are investing heavily in, mentioning potential up and comers in various industries.  Brush also looks at Lindsay Rosenwald’s selling record (as well as the selling record of other insiders) in order to see a pattern of what may be wise to drop.

The article proceeds to mention Lindsay Rosenwald‘s background as a venture capitalist, and his work in the finance and medical industries.  He talks about the longer track record that gives Rosenwald some definite bragging rights when it comes to investment in the Biotech industry.  He goes into detail on one recent investment (in the company Genta) and what it may mean for potential investors in the industry.

Michael Brush goes into detail on the background of other investors and their major investments (as well as payoffs), including Tom Ward, Phillip Frost, David Rafael Lewis, Shahin Hedayat, Thomas Smach, and Naveen Jain.  In the list, he calls Lindsay Rosenwald the “top all-star.”